oxamflatin profile

oxamflatin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5353852
CHEMBL ID	98245
CHEBI ID	93779
SCHEMBL ID	1232655
SCHEMBL ID	1232657
MeSH ID	M0264203

Synonym
oxamflatin
NCGC00165855-01 ,
2-penten-4-ynamide, (2e)-
151720-43-3
nsc729360
nsc-729360
(e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide
A809210
(e)-5-[3-(benzenesulfonamido)phenyl]pent-2-en-4-ynehydroxamic acidn-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2e-penten-4-ynamide; metacept 3
CHEMBL98245
(2e)-5-[3-(phenylsulfonylamino)phenyl]-pent-2-en-4-ynohydroxamic acid
AKOS015899715
mfcd00949087
BRD-K14221870-001-01-6
CCG-208700
SCHEMBL1232655
SCHEMBL1232657
DTXSID40417739
QRPSQQUYPMFERG-LFYBBSHMSA-N
n-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2e-penten-4-ynamide
5ok ,
CHEBI:93779
oxamflatin, >=98% (hplc), solid
J-008835
HY-102033
CS-6980
(e)-n-hydroxy-5-(3-(phenylsulfonamido)phenyl)pent-2-en-4-ynamide
BCP20651
2-penten-4-ynamide,n-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-,(2e)-
EX-A1442
nsc 729360
metacept 3
metacept-3
Q27455909
MS-25240
AC-36464
BGA72043
[(phenylsulfonyl)amino]phenyl]-, (2e)-
2-penten-4-ynamide, n-hydroxy-5-[3-
934986-71-7
n-hydroxy-5-(3-(phenylsulfonamido)phenyl)pent-2-en-4-ynamide

Research Excerpts

Overview

Oxamflatin is a histone deacetylase inhibitor that has been suggested as a promising anti-tumor agent. Its effect on the viability and invasion of gastric tumor cells is unclear.

Excerpt	Reference	Relevance
"Oxamflatin is a histone deacetylase inhibitor that has been suggested as a promising anti-tumor agent; yet its effect on the viability and invasion of gastric tumor cells is unclear."	( The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Araei, Y; Faghihloo, E; Mirzaei, H; Mohammadi, HR; Mohammadi, M; Mokhtari-Azad, T, 2016)	1.52

Treatment

Oxamflatin treatment enhanced blastocyst formation of SCNT embryos in vitro. In oxam flatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene.

Excerpt	Reference	Relevance
"Oxamflatin treatment enhanced blastocyst formation of SCNT embryos in vitro."	( Oxamflatin treatment enhances cloned porcine embryo development and nuclear reprogramming. Lee, K; Mao, J; Murphy, CN; O'Gorman, C; Prather, RS; Rivera, RM; Samuel, MS; Spate, LD; Walters, EM; Wells, K; Whitworth, KM; Zhao, MT, 2015)	2.58
"In oxamflatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene by junD via cyclic AMP responsive element in its promoter."	( Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. Nishida, K; Ohtani, M; Sonoda, H; Sugita, K; Yoshioka, T, 1996)	2.25
"Treatment of oxamflatin decreased the relative histone deacetylase (HDAC) activity in cloned embryos and resulted in hyperacetylation levels of histone H3 at lysine 9 (AcH3K9) and histone H4 at lysine 5 (AcH4K5) at pronuclear, two-cell, and four-cell stages partly through downregulating HDAC1."	( Effects of histone deacetylase inhibitor oxamflatin on in vitro porcine somatic cell nuclear transfer embryos. Hou, L; Ma, F; Ma, Z; Ren, Z; Riaz, H; Wang, Y; Wu, W; Xia, X; Xiong, Y; Xu, D; Yang, J; Ying, W; Zhang, L; Zhou, Y; Zuo, B, 2014)	1.02
"Treatment with oxamflatin also led to decreased cell viability."	( HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines. Dai, ZJ; Fu, RG; Jing, YY; Li, Y; Liui, HL; Ren, HT; Wang, YL; Wang, ZW, 2016)	1.13

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	31.6228	0.0040	23.8416	100.0000	AID485290
ATAD5 protein, partial	Homo sapiens (human)	Potency	9.4672	0.0041	10.8903	31.5287	AID624252; AID720565
PPM1D protein	Homo sapiens (human)	Potency	2.5503	0.0052	9.4661	32.9993	AID1347411
shiga toxin 1 variant A subunit	Escherichia coli O157:H7	Potency	11.2728	5.0354	16.1932	32.6037	AID2320
shiga toxin 1 B subunit	Escherichia coli O157:H7	Potency	11.2728	5.0354	13.8488	22.4921	AID2320
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	6.3096	0.0165	25.3078	41.3999	AID602332
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	0.2818	0.0100	39.5371	1,122.0200	AID1479
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	5.0173	0.0079	8.2332	1,122.0200	AID2546; AID2551
Interferon beta	Homo sapiens (human)	Potency	2.5503	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (7.69)	18.2507
2000's	10 (38.46)	29.6817
2010's	11 (42.31)	24.3611
2020's	3 (11.54)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.46	2	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source	3.02	4	isoquinolines
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.44	2	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.06	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.25	1	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.02	1	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.97	4	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
belinostat [no description available]	2.05	1	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.02	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.41	2
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.01	1
apicidin apicidin: structure in first source	2.06	1

Condition	Relationship Strength	Studies
Becker Muscular Dystrophy [description not available]	2.25	1
Muscular Dystrophy, Duchenne An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)	2.25	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.49	2
Cancer of Stomach [description not available]	2.13	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.13	1
Cancer of Liver [description not available]	2.05	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.05	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.05	1
HIV Coinfection [description not available]	2.06	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.06	1
ATLL [description not available]	2.01	1
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	2.01	1
Metastase [description not available]	2.02	1
Invasiveness, Neoplasm [description not available]	2.02	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.02	1
Germinoblastoma [description not available]	2.02	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.02	1
Cancer of Endometrium [description not available]	2.03	1
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.03	1
Thrombopenia [description not available]	2.03	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.03	1
B-Cell Lymphoma [description not available]	2.04	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.04	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	1.99	1
B16 Melanoma [description not available]	2	1
Peritoneal Carcinomatosis [description not available]	2	1
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2	1
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	2	1

oxamflatin

Description

Cross-References

Synonyms (41)

Research Excerpts

Overview

Treatment

Protein Targets (9)

Potency Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (3)

Research

Studies (26)

Market Indicators

Research Demand Index: 20.90

Study Types

oxamflatin

Description

Cross-References

Synonyms (41)

Research Excerpts

Overview

Treatment

Protein Targets (9)

Potency Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (3)

Research

Studies (26)

Market Indicators

Research Demand Index: 20.90

Study Types

Related Drugs (13)

Related Conditions (28)